Literature DB >> 17956895

CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro.

Julie van der Zee1, Hazel Urwin, Sebastiaan Engelborghs, Marc Bruyland, Rik Vandenberghe, Bart Dermaut, Tim De Pooter, Karin Peeters, Patrick Santens, Peter P De Deyn, Elizabeth M Fisher, John Collinge, Adrian M Isaacs, Christine Van Broeckhoven.   

Abstract

The charged multivesicular body protein 2B gene (CHMP2B) was recently associated with frontotemporal lobar degeneration (FTLD) linked to chromosome 3 in a Danish FTLD family (FTD-3). In this family, a mutation in the acceptor splice site of exon 6 produced two aberrant transcripts predicting two C-truncated CHMP2B proteins due to a read through of intron 5 (p.Met178ValfsX2) and a cryptic splicing event within exon 6 (p.Met178LeufsX30). Extensive mutation analysis of CHMP2B in Belgian patients (N = 146) identified one nonsense mutation in exon 5 (c.493C>T) in a familial FTLD patient, predicting a C-truncated protein p.Gln165X analogous to the Danish mutant proteins. Overexpression of Belgian p.Gln165X in human neuroblastoma SK-N-SH cells showed the formation of large, aberrant endosomal structures that were highly similar to those observed for Danish p.Met178ValfsX2. Together, these data suggest that C-truncating mutations in CHMP2B might underlie the pathogenic mechanism in FTLD by disturbing endosome function. We also describe a missense mutation in exon 5 of CHMP2B (p.Asn143Ser) in a familial patient with cortical basal degeneration. However, the pathogenic character of this mutation remains elusive.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956895     DOI: 10.1093/hmg/ddm309

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  54 in total

Review 1.  Multivesicular bodies in neurons: distribution, protein content, and trafficking functions.

Authors:  Christopher S Von Bartheld; Amy L Altick
Journal:  Prog Neurobiol       Date:  2011-01-07       Impact factor: 11.685

Review 2.  TDP-43 and frontotemporal dementia.

Authors:  William T Hu; Murray Grossman
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

3.  CHMP2B mutations are rare in French families with frontotemporal lobar degeneration.

Authors:  Mustapha Ghanim; Léna Guillot-Noel; Florence Pasquier; Ludmila Jornea; Vincent Deramecourt; Bruno Dubois; Isabelle Le Ber; Alexis Brice
Journal:  J Neurol       Date:  2010-07-14       Impact factor: 4.849

Review 4.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

5.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

Review 6.  New approaches to the treatment of frontotemporal lobar degeneration.

Authors:  Keith A Vossel; Bruce L Miller
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

7.  Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations.

Authors:  Hazel Urwin; Astrid Authier; Jorgen E Nielsen; Daniel Metcalf; Caroline Powell; Kristina Froud; Denise S Malcolm; Ida Holm; Peter Johannsen; Jeremy Brown; Elizabeth M C Fisher; Julie van der Zee; Marc Bruyland; Christine Van Broeckhoven; John Collinge; Sebastian Brandner; Clare Futter; Adrian M Isaacs
Journal:  Hum Mol Genet       Date:  2010-03-10       Impact factor: 6.150

8.  FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.

Authors:  Hazel Urwin; Keith A Josephs; Jonathan D Rohrer; Ian R Mackenzie; Manuela Neumann; Astrid Authier; Harro Seelaar; John C Van Swieten; Jeremy M Brown; Peter Johannsen; Jorgen E Nielsen; Ida E Holm; Dennis W Dickson; Rosa Rademakers; Neill R Graff-Radford; Joseph E Parisi; Ronald C Petersen; Kimmo J Hatanpaa; Charles L White; Myron F Weiner; Felix Geser; Vivianna M Van Deerlin; John Q Trojanowski; Bruce L Miller; William W Seeley; Julie van der Zee; Samir Kumar-Singh; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Eileen H Bigio; Han-Xiang Deng; Glenda M Halliday; Jillian J Kril; David G Munoz; David M Mann; Stuart M Pickering-Brown; Valerie Doodeman; Gary Adamson; Shabnam Ghazi-Noori; Elizabeth M C Fisher; Janice L Holton; Tamas Revesz; Martin N Rossor; John Collinge; Simon Mead; Adrian M Isaacs
Journal:  Acta Neuropathol       Date:  2010-05-20       Impact factor: 17.088

Review 9.  The role of CHMP2BIntron5 in autophagy and frontotemporal dementia.

Authors:  Christopher S Krasniak; S Tariq Ahmad
Journal:  Brain Res       Date:  2016-03-10       Impact factor: 3.252

10.  Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS).

Authors:  Laura E Cox; Laura Ferraiuolo; Emily F Goodall; Paul R Heath; Adrian Higginbottom; Heather Mortiboys; Hannah C Hollinger; Judith A Hartley; Alice Brockington; Christine E Burness; Karen E Morrison; Stephen B Wharton; Andrew J Grierson; Paul G Ince; Janine Kirby; Pamela J Shaw
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.